Get the Daily Brief
Latest Biotech News
SPARK trial: Sitravatinib plus tislelizumab shows activity in TNBC
The SPARK phase II multi-cohort single-arm trial reported activity for the combination of sitravatinib, a broad-spectrum tyrosine kinase modulator, with tislelizumab, an anti–PD‑1 antibody, in...
NK cell infusion shows safety signals in post‑transplant liver cancer
A phase I study of natural killer (NK) cell infusion in patients with recurrent hepatocellular carcinoma (HCC) after liver transplantation reported tolerability and preliminary antitumor signals....
Gut microbes shape cancer immunity — metabolites and population genomes
Two microbiome studies published recently advance links between gut communities and disease. Liu et al., in Molecular Cancer, reported that gut microbial metabolites modulate antitumor immunity,...
AI models sharpen proteomics and chromatin prediction
Two new computational tools apply machine learning to core molecular problems. ProteoBoostR debuted as an interactive supervised‑ML framework designed for clinical proteomics workflows, enabling...
Stroma and epigenetics drive lung cancer spread
Two mechanistic oncology studies identify non‑tumor drivers of metastasis. Rasbach et al. showed that a tumor‑intrinsic ITGB2 axis can be inhibited to suppress melanoma growth, revealing adhesion...
Moderna scales back vaccine investments amid US backlash
Moderna’s CEO told Bloomberg the company is curbing investments in some vaccine trials in response to political and public backlash in the United States. The shift reflects pressure on mRNA...
Biotech cash sprint: Erasca raises $258.8M – Corxel banks $287M
Biotech capital markets delivered two large financing events this week. Erasca closed an upsized public offering of 25.875 million shares at $10.00 per share, generating roughly $258.8 million in...
Appeals court remands Guardant-TwinStrand feud: patent validity sent back to PTAB
A U.S. appeals court has remanded parts of the patent dispute between Guardant Health and TwinStrand Biosciences back to the Patent Trial and Appeal Board (PTAB) for further consideration. The...
Encodia shutters: protein sequencing start‑up ceases operations
Encodia, a San Diego firm developing ProteoCode DNA‑tagged peptide protein sequencing, has ceased operations and entered an assignment for the benefit of creditors. The company, launched by...
Novartis expands RNAi push — CEO outlines de‑risking strategy
Novartis signaled an expanded commitment to RNA interference (RNAi) as a therapeutic modality, with CEO Vas Narasimhan describing a deliberate, de‑risking approach to build on recent modality...
Sanofi moves forward with amlitelimab filings... despite mixed Phase III reads
Sanofi announced plans to pursue global regulatory submissions for amlitelimab in atopic dermatitis, citing the totality of data despite mixed Phase III results. The OX40‑ligand inhibitor met...
Macrophage‑targeting CAR T reprograms tumor microenvironment — survival improves in models
Researchers at the Icahn School of Medicine reported an experimental CAR T approach that targets tumor‑associated macrophages (TAMs) and secretes IL‑12, reprogramming the tumor microenvironment...
NK cell infusions show promise in liver cancer post‑transplant trial
A phase I study explored adoptive Natural Killer (NK) cell infusions for hepatocellular carcinoma (HCC) in patients with recurrent disease after liver transplantation. Investigators reported...
SPARK trial: sitravatinib plus tislelizumab shows activity in recurrent/metastatic TNBC
Interim results from the SPARK phase II trial report clinical activity for the combination of sitravatinib, a spectrum kinase inhibitor, with tislelizumab, an anti‑PD‑1 antibody, in patients with...
EU launches FAST‑EU pilot to accelerate multinational clinical trials
The European Union unveiled FAST‑EU, a voluntary pilot designed to shorten startup timelines for multinational clinical trials to a maximum 70 days for certain studies. The pilot will fast‑track...
New products roll: Tempus AI, Navinci Diagnostics, Parse Biosciences and Zepto Life launch clinical tools
Several commercial product launches broaden diagnostic and spatial biology toolsets for translational research and clinical labs. Tempus AI introduced Paige Predict, an AI suite that estimates 123...
Erasca closes upsized offering — $258.8M raised
Erasca announced the closing of an upsized public offering that generated approximately $258.8 million in gross proceeds. The clinical-stage precision oncology company, focused on RAS/MAPK pathway...
Corxel banks $287M to push oral GLP‑1
Corxel Pharmaceuticals closed a $287 million Series D financing to advance CX‑11, an oral small‑molecule GLP‑1 receptor agonist, through U.S. and global phase II trials and to prepare for phase...
Sanofi presses forward: filings eyed for amlitelimab after mixed Phase 3
Sanofi said it will pursue regulatory submissions for amlitelimab in atopic dermatitis despite mixed results across its Phase 3 program. The company cited the totality of the data and signaled...
Wegovy pill takes off: prescriptions surge in second week
Novo Nordisk reported a rapid uptake of its oral Wegovy launch, with prescriptions rising roughly 500% in the product’s second week and prescriptions surpassing 18,000 in the same period. The...